Background Studies have shown disparate results in relation to the role of plasma concentrations of cell adhesion molecules in atherosclerosis. Moreover, the differentiation of primary vs secondary alterations of these markers, in response to myocardial injury, has not been clear. We measured specific soluble cell adhesion molecules and inflammatory markers in men admitted acutely with chest pain and compared them to healthy controls.
Background Studies have shown disparate results in relation to the role of plasma concentrations of cell adhesion molecules in atherosclerosis. Moreover, the differentiation of primary vs secondary alterations of these markers, in response to myocardial injury, has not been clear. We measured specific soluble cell adhesion molecules and inflammatory markers in men admitted acutely with chest pain and compared them to healthy controls.
Methods and Results
We prospectively studied men (total n=241), admitted acutely with chest pain (7·4 9·4 h, 71% within 10 h), unstable angina (n=67), acute myocardial infarction (n=47) and chest pain without ischaemic heart disease (n=45) and compared them with a stratified sample of randomly selected healthy controls (n=82). Soluble intercellular adhesion molecule (sICAM-1), endothelial selectin, vascular cell adhesion molecule, interleukin-6 and C-reactive protein were measured by ELISA and P-selectin expression by flow cytometry. Multiple regression analysis was used to control for the impact of classical risk factors. At baseline ICAM-1, interleukin-6 and C-reactive protein were significantly elevated in patient groups whereas no difference in vascular cell adhesion molecule or endothelial selectin was found. At 3 month follow-up, ICAM-1 level was unchanged in ischaemic heart disease patients. In all groups C-reactive protein and interleukin-6 levels were lower at review. ICAM-1 levels at follow-up were higher in ischaemic heart disease groups (but not in chest pain without ischaemic heart disease) relative to controls and remained so only in the unstable angina group following regression. sICAM-1, interleukin-6 and C-reactive protein strongly correlated with smoking. In the acute phase, ICAM-1 was confounded by smoking following regression and C-reactive protein and interleukin-6 remained significant in both ischaemic heart disease groups after multiple regression. There was no relationship to events which occurred in 23% of ischaemic heart disease patients (further acute myocardial infarction 5·3%, sudden cardiac death 0·9% or recurrent angina 16·7%).
Introduction
Atherosclerosis is increasingly considered as a low grade inflammatory response of the arterial wall to a variety of stimuli [1] . In the acute coronary syndrome there is an unexpected and sudden development of ischaemia which has been attributed to plaque rupture and subsequent thrombosis, although this theory has been challenged. Indeed some autopsy studies have failed to identify fissures associated with 10% to 40% of coronary thrombi in patients with fatal myocardial infarction. Conversely, plaque fissuring may be found in 10-25% of patients dying from non-cardiac causes [2] . The potential role of inflammation and cell adhesion molecules has become increasingly recognised in cardiovascular disease [3] but only a few studies [4] [5] [6] have evaluated the soluble levels in patients with the acute coronary syndromes. Both ICAM-1 and endothelial selectin are expressed on activated endothelium to facilitate localization of leukocytes to the site of injury. ICAM-1 is required for the migration of leukocytes out of the circulation into the myocardium where they may cause damage by release of toxic metabolites [7] . Soluble levels of cell adhesion molecules shed from activated cells can now be quantified [8] relatively easily but their exact role has not been clarified in the acute coronary syndrome. Initial studies suggested associations [4] [5] [6] but were limited by small numbers, inadequate control populations and delayed sampling in relation to the index pain. By studying patients early following chest pain this study aimed to clarify the role of the inflammatory process early after clinical initiation of the acute coronary syndrome. We focused on circulating levels of both cellular and plasma markers of inflammation which could point to an augmented propensity for platelet, leukocyte and endothelial interactions via specific membrane receptors. The mechanism by which these cells become activated with receptor up-regulation is only partially understood but it is clearly related to genetic factors and environmental influences, for example certain mediators such as interleukin-6. The potential importance of these receptors have been shown in the beneficial therapeutic responses to blockade of the platelet fibrinogen receptor (glycoprotein IIb/IIIa) in patients with unstable angina [9] . Interest has also focused on other inflammatory markers such as C-reactive protein and interleukin-6 in patients with the acute coronary syndromes [10] [11] [12] [13] [14] [15] [16] [17] [18] , with studies mainly concentrating on the predictive value of these markers. The question remained as to whether sufficient concentrations of specific inflammatory markers exist in the circulation to identify patients with the acute coronary syndrome. We were concerned with establishing whether soluble cell adhesion molecules were risk factors using a well designed case-control study. Secondly we wanted to determine the relationship of these markers to classical risk factors. And lastly in a prospective manner we wanted to document the relationship to short-term cardiovascular outcome. In this case-control study of Edinburgh men we measured soluble levels of ICAM-1, vascular cell adhesion molecule, endothelial selectin, P-selectin expression on platelets together with the cytokine interleukin-6 and C-reactive protein. The cases were unselected emergency admissions to a teaching hospital with healthy randomly selected controls from the same demographic area.
Methods

Clinical investigation
We studied men aged <65 years admitted acutely to the Royal Infirmary of Edinburgh with chest pain. They were classified as unstable angina with corroborative evidence of ischaemic heart disease, acute myocardial infarction, or chest pain with suspected myocardial ischaemia. Unstable angina was defined as recent onset (<48 h previously) prolonged (>10 min) or recurrent (>2 episodes lasting >5 min in any one day) anginal chest pain at rest with evidence of ischaemic heart disease equivalent to grade IIIB Braunwald classification [19] . 'Definite' ischaemic heart disease was shown by one or more of the following: ECG changes in at least two contiguous leads during anginal pain; prior history of myocardial infarction; history of typical exertional angina; previous coronary angiography showing >50% narrowing in any major artery; previous positive exercise test. Acute myocardial infarction was defined by typical ECG changes (12 lead ECG) and/or rise in serum creatine kinase. Chest pain with suspected myocardial ischaemia; this included males admitted to hospital with no independent evidence of ischaemic heart disease. This group provided a heterogeneous hospital control sample.
An additional group consisted of an age-stratified sample of healthy Edinburgh men (n=300) randomly selected from the Lothian Health Board register (total population 500 000) to act as healthy community controls. Of those invited 27% attended, 23% were deemed unsuitable by their general practitioner, 12% refused, 13% could not be traced and no response was obtained from the remaining 25%. Men (a high risk population) less than age 65 years of age were studied in order to obtain a sample who would be free from complex medical disorders or nutritional problems common in older patients.
Exclusion criteria: we excluded patients on anticoagulants; with a history of previous deep venous thrombosis or stroke, diabetes, previous coronary artery bypass grafting, haematological disorder or malignancy. Baseline demographic and anthropometry were recorded. Blood pressure was recorded using a random zero Hawksley manometer at three monthly review and in healthy controls.
Laboratory investigation Acute admission
All patients who joined the study were asked to donate a blood sample prior to initiation of treatments in hospital. They were invited to re-attend a clinic at 12 weeks for repeat sampling to confound for changing levels of parameters and blood pressure in the acute phase of hospital admission. Patients who suffered an extension of their first infarct were studied 12 weeks after such an event.
Soluble ICAM-1 (intra-assay/inter-assay precision is quoted as 4·8%/7·4%), vascular cell adhesion molecule-1 (5%/9·2%), endothelial selectin (4·8%/9·2%) and interleukin-6 (6·9%/14%) were evaluated by ELISA (R & D Systems Europe Ltd, Oxon, U.K.). C-reactive protein (5·1%/14·3% and <5 g . ml 1 defined as normal) was
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evaluated by ELISA (Eurogenetics UK. Hampton.). P-selectin was measured on platelets using single fluorescence flow cytometry on a Becton Dickson FACS scanner, based on methods described by Warkentin and Janes [20, 21] . Special care was taken with sample handling. Blood samples were taken using a wide bore needle and minimal tourniquet pressure. Blood was mixed with trisodium citrate anticoagulant and processed without fixatives within 10 min of venepuncture. An electronic gate was set around the platelet population and 5000 platelets analysed. Using the sample containing isotypic control the photo-multiplier tubes were calibrated for each individual patient. P-selectin was expressed as the percent positive particles, defined as those with a fluorescence intensity exceeding 99% of platelets containing the isotypic control. Expression of glycoprotein GpIb was used to confirm 98% of particles as platelets. It is a whole blood method without fixatives, platelet inhibitors or centrifugation steps. Total cholesterol, high density lipoprotein (HDL) and derived low density lipoprotein (LDL) were evaluated by precipitation and enzymatic analysis using a Cobas Bio centrifugal analyser.
Follow-up: 3 months
At 3 months the patients were asked to attend for review, fasting for 12 h, and to abstain from smoking, caffeine and alcohol for the same period. They were rested on a couch for 15-20 min prior to venepuncture. The controls were treated in the same way. The plasma levels of sICAM-1, interleukin-6 and C-reactive protein were repeated in chest pain patients. Only one measurement was performed in the healthy controls.
Definition of events
Cardiovascular event rate was recorded at the 12 week review. These were defined as further acute myocardial infarction, sudden cardiac death or recurrent unstable angina. Recurrent unstable angina was defined as the occurrence of symptoms equivalent to Braunwald IIIB as before and which led to urgent hospital admission.
Statistics
Differences between groups were analysed using Chisquared or Mann-Whitney tests as appropriate, and Bonferroni corrections were used to adjust for the fact that six pairwise group comparisons were made for each factor. Spearman rank correlation was used to assess the significance of associations between classical risk factors and inflammatory markers. To adjust for possible confounding between the classical risk factors and inflammatory markers, a series of multiple regressions was carried out for the two primary pairwise group comparisons (i.e. unstable angina cases compared to controls and acute myocardial infarction cases compared to controls). For each inflammatory marker separately, the logarithm of the marker level was regressed against all the risk factors listed in Table 1 , and also a dummy variable identifying whether the subject was a case or control. The results of these regressions are expressed as confidence limits for the mean marker level in cases, as a percentage of the mean level in controls, by taking antilogarithms of the regression coefficients for the dummy variables representing casehood. Paired Wilcoxon tests were used to compare the levels of markers in patients at admission and at 3 months. For the purpose of outcome the event rate of the unstable angina and acute myocardial infarction groups were taken together.
Ethical approval
The study was approved by the Lothian ethics committee. Patients gave written consent prior to entry to the study. Figure 1 shows the distribution of the onset of chest pain in hours prior to admission. For the whole sample, patients were admitted within 7·4 9·4 h (mean SD) and 71% were admitted within 10 h. The delay from onset of the index chest pain to admission was greater in the unstable angina and chest pain without ischaemic heart disease patients compared to the acute myocardial infarction group, as shown in Table 1 . The delay was also greater in the chest pain without ischaemic heart disease patients compared to the unstable angina group also.
Results
Time of chest pain
The baseline demographic data of the patient groups and community controls are shown in Table 1 . Those with unstable angina or acute myocardial infarction were more likely to have a history of hypertension, family history of ischaemic heart and peripheral vascular disease. Current smoking was more common in the acute myocardial infarction group, whereas the unstable angina and controls had a higher prevalence of exsmokers. The presence of hyperlipidaemia, high alcohol intake, family history of other vascular disease e.g. stroke, low fat diet or never-smoked status was equal among groups. On admission to hospital, all three patient groups had higher diastolic and systolic pressures compared to community controls. Regular prescription of aspirin prior to admission occurred in 60% of unstable angina, 29% of acute myocardial infarction and 5% of chest pain without ischaemic heart disease patients. During the hospital stay, 27% of ischaemic heart disease patients received intravenous heparin and 33% nitrates. At the time of discharge there was no difference in the prescription of other drugs, such as lipid lowering, beta-blockers or angiotension converting enzyme agents.
The plasma levels of sICAM-1, interleukin-6 and C-reactive protein on admission were higher in all three groups than in the healthy controls (Table 1 , Fig.  2(a-c) ). In the unstable angina group, 27% had a C-reactive protein value >the upper limit of 5 g . ml 1 compared to 30% for the study population as a whole. At 3 month review, the interleukin-6 and C-reactive protein had fallen (Fig. 2b and c) , but ICAM-1 remained elevated in all patient groups (Figs. 2a) ) relative to the acute phase level. Review levels were compared to healthy control and after Bonferroni corrections the following were significant: sICAM-1 in unstable angina and acute myocardial infarction vs control (238·6 69·1, 234·7 53·5, vs 204·3 51 ng . ml 1 P<0·01). There was no difference noted between the ischaemic heart disease groups at review. The logistic regressions of review levels adjusted for confounders showed sICAM-1 to be elevated in unstable angina only (P<0·01). The other adhesion molecules were not elevated on admission and the mean plasma levels were similar to community controls (vascular cell adhesion molecule-1, unstable angina 450 139, acute myocardial infarction 450 138, chest pain without ischaemic heart disease 426 126, community controls 438 118 ng . ml 1 , mean SD; endothelial selectin, unstable angina 50 22, acute myocardial infarction 48 20, chest pain without ischaemic heart disease 50 20, community controls 45 17 ng . ml 1 ) Table 1 . The expression of P-selectin on platelets was similar in each patient group where compared to community controls (unstable angina 8·2% 6·2%, acute myocardial infarction 6·0% 4·6%, chest pain without ischaemic heart disease 7·4% 4·8%, community controls 7% 5·0%). Total cholesterol and triglycerides were higher in unstable angina and acute myocardial infarction groups whereas HDL cholesterol levels were similar (Table 1) .
Correlations were sought by univariate analysis between the concentrations of adhesion molecules and patient clinical characteristics. The sICAM-1, interleukin-6 and C-reactive protein were strongly 
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correlated with smoking (r=0·47 P<0·01, r=0·23 P<0·01, r=0·27 P<0·01 respectively). The sICAM-1 and C-reactive protein were also correlated with triglycerides (r=0·28, P<0·01 r=0·21, P<0·01, respectively), endothelial selectin correlated with body mass index (r=0·26, P<0·01) and vascular cell adhesion molecule-1 and age (r=0·21, P<0·01). The results of multiple regressions are shown in Table 2 . In the acute phase, sICAM-1 was confounded by smoking and was not significant after adjustment for this factor. Both C-reactive protein and interleukin-6 remained significant following adjustment for potential confounders. The multiple regressions have been tabulated in Table 2 .
Relationship of the adhesion molecule concentrations to short-term cardiovascular events
There was no relationship to short-term cardiovascular outcome for any of the inflammatory markers, or after multiple regressions were performed. The event rates are shown in Table 3 .
Discussion
The clinical syndromes of unstable angina and acute myocardial infarction are heterogeneous in the distribution and relative importance of various pathogenetic triggers. Recent studies in unstable coronary disease have suggested a role for inflammatory markers such as sICAM-1 [4] [5] [6] , C-reactive protein [11] [12] [13] [14] 16] and interleukins 1 and 6 [17, 18] in this process. Additional support for an inflammatory role comes from preliminary studies suggesting that treatment with a macrolide antibiotic, for at least 6 months, is associated with clinical benefit in patients with acute non-Q wave coronary syndrome, ROXIS (the pilot study) [23, 24] . What is not clear is whether this inflammatory response is the cause or the result of the acute event. The predictive value of inflammatory markers in both acute [13] and cohort studies [25, 26] has been established but their value as risk factors in patients who present early with chest pain is unclear.
Here we evaluated systemic plasma levels of soluble adhesion markers in Edinburgh men with chest pain syndromes, comparing them to a carefully selected control population from the same demographic area. Also 
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we report significant early elevations of sICAM-1 in patients with the chest pain syndrome which persists beyond the acute phase. This confirms the results of previous studies [4] [5] [6] which have, however, had some limitations. They were smaller and the timing of sampling in relation to the index pain was unclear. The point in time in relation to chest pain is important when interpreting the possible effects of the acute phase response. An important difference from previous studies is the early sampling performed here. We sampled patients early following index pain, 71% within 10 h (Fig. 1 ). This contrasts with previous studies who admitted patients selected for angiography [4, 25] , inevitably involving a further time delay. The three chest pain groups studied provided patients with a graduated risk of clinical events. Even the patients without independent clinical evidence of ischaemic heart disease could be considered at relatively higher risk (Berkson-selection bias [27] ) than healthy controls. Furthermore it is possible that some of these patients might have had mural thrombosis not associated with plaque rupture. They displayed changes in sICAM-1 which were unchanged at 3 month follow-up relative to the acute phase but were not different from healthy controls. This is in contrast to patients with definite ischaemic heart disease. Interestingly, sICAM-1 was unchanged by the acute phase and remained higher at 3 month follow-up compared to healthy controls in both the unstable angina and acute myocardial infarction groups. Notwithstanding the strong relationship with smoking demonstrated on multiple regression analysis, this provides good evidence implicating sICAM-1 levels in the development of the acute coronary syndrome. In view of the mounting evidence for the role of inflammation it is biologically plausible that initiating events in the acute coronary syndrome may relate to leukocyte binding mediated by ICAM-1. A plasma factor such as this, which we have shown is not affected by the acute event and is systematically distinct from healthy controls, has a high likelihood of being a significant risk factor. We chose, as healthy controls, men (a high risk, group) who would be free of complex medical pathology and nutritional problems which tend to occur in older people. The response rate of almost 30% is average for this type of study. It could be argued that this 'healthy' control group were not representative of the at-risk population because of this response rate and that these volunteers are more likely to be health conscious. This form of bias is an unavoidable feature of this type of study, but we managed to match cases/controls for age sex and demographic characteristics to reduce this problem.
The relationship of these markers to smoking and other classical risk factors has not been previously reported in the acute coronary syndrome. It is possible that smoking mediates at least part of its detrimental effects via this mechanism. The prothrombotic effects of smoking are well documented but perhaps this role is also important. sICAM-1 is the major ligand for localization of leukocytes to activated endothelium, and expression has been documented on atherosclerotic plaques [28] . Targeting of sICAM with monoclonal antibodies has been shown to limit infarct size or reduce reperfusion injury [29, 30] . More important is the early sampling, indicating this interaction may be an early initiating event which could be targeted with monoclonal antibodies. In our study the usefulness of vascular cell adhesion molecule-1 has not been confirmed as previously suggested [4] , but accords with two other studies of patients with atherosclerosis [31] [32] [33] . Our study adds to the evidence that plasma levels of vascular cell adhesion molecule-1 are not important in the interaction between inflammation and atherothrombosis. Similarly endothelial selectin levels were not different between the patient groups and this may reflect the fact that adhesion with selectins is weaker and more transient to enable cells to roll along the vascular endothelium. P-selectin levels on platelets were similar in patient groups in distinction from other reports [34] [35] [36] . The lack of platelet activation may relate to early sampling or downregulation of the P-selectin receptor, occurring as the activated platelets are consumed due to mural thrombosis.
Most studies have reported high levels of C-reactive protein in patients with unstable angina [13] which may help to predict outcome [11] [12] [13] [14] [15] [16] . Interleukin-6, a cytokine produced in the liver, is thought to regulate the acute phase response in patients with acute myocardial infarction [37] and higher levels have been found in unstable angina patients [17, 18] . Our results show elevated levels of both C-reactive protein and interleukin-6, but we have also demonstrated that the levels are lower at 3 month follow-up when they were similar at this point to healthy controls. We did not find any relationship to outcome, although the numbers and clinical event rate are relatively small. In this study the data suggest that the magnitude of the acute phase response we observed was small and may reflect earlier sampling. Similar to sICAM-1 both interleukin-6 and C-reactive protein were strongly correlated with smoking, again reflecting a pro-inflammatory state. Both C-reactive protein and interleukin-6 remained significant as risk factors following multiple regression analysis. However their review levels, at 3 months, were no different from controls and a second regression on follow-up levels showed that the review level (C-reactive protein and interleukin-6) did not become significant in any of the patient groups when adjustment was made for classical risk factors. Although related to smoking in univariate analysis, the levels were clearly elevated in the acute phase without confounders, indicating a possible role in the pathophysiology of this syndrome. Both markers could have a causal role in the acute coronary syndromes as the fall at review may represent the beneficial effects of various medical interventions such as aspirin. In the population as a whole and unstable angina group only, 30% and 27% (respectively) had C-reactive protein values greater than the upper limit of 5 g . ml 1 , resulting in a minimal acute phase reaction in comparison to a previous study which reported elevations of C-reactive protein in 50-70% of patients with unstable angina [13] . The levels in the chest pain without ischaemic heart disease group, who received minimal medical therapy, also dropped suggesting that these markers are acute phase reactants in addition to their possible initiating role. The changes observed may reflect an early pro-inflammatory state, with smoking, infection or unknown precipitants, which may have caused the chest pain syndromes.
Our study may be limited by a number of factors. Statistical analysis involved multiple testing with Bonferroni corrections and could have led to positive results occurring by chance. Additionally the comparison of follow-up levels, as a surrogate of what might be likely before the acute event, with a second regression, may be difficult to interpret as the 'event' or medical intervention may change the marker level. With the small numbers and short follow-up involved, the study is not powered to show the relationship to cardiac events. The hospitalized groups were a survivor population by definition and are therefore a lower risk group; the levels in patients that suffer sudden cardiac death may have been higher. Our main aim related to establishing whether these markers were risk factors and this issue has been answered.
In conclusion, we found evidence of an early rise in levels of sICAM-1, interleukin-6 and C-reactive protein in patients with the acute coronary syndromes. The results suggest that the pro-inflammatory state, especially the binding of leukocytes to the vascular endothelium, has an important role in patients with unstable coronary artery disease. Targeting of this interaction may have further therapeutic potential for patients.
